# Pizarra — PT-pseudo_36c92fb424ac (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_36c92fb424ac
Task: 1

Encounter: Urology - outpatient on 20 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.32 ng/mL/yr
  - Prior PSA: 5.4 ng/mL
  - Prostate volume: 79.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7697653 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Obesity (BMI >30), Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Obesity (BMI >30), Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 79 mL. csPCa 0.77.

Vitals: weight 94 kg, height 184 cm, BMI 27.8, BP 123/65 mmHg, HR 58 bpm. Smoking: Ex-smoker (36 pack-yr, quit 2005).

Chief complaint: Ongoing PSA elevation combined with a previous negative biopsy necessitates clinical reassessment.

History: Initial evaluation for elevated PSA began in late 2022. This 67-year-old gentleman has completed a negative biopsy and returns now for reassessment. A retired police officer, he is married and resides alone. He walks daily for 45 minutes and abstains completely from alcohol. Lower urinary tract symptoms (IPSS 19/35) remain moderate and are effectively managed with tamsulosin. His active medications consist of atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, and tamsulosin. Comorbidities include hypercholesterolaemia, chronic kidney disease, obesity (BMI >30), osteoarthritis, and benign prostatic hyperplasia. He quit smoking in 2005 after a 36 pack-year history. He completed a six-session physiotherapy regimen for stable lower back discomfort that holds no relation to his urological concerns. Routine podiatry visits maintain his foot health. Residing over 90 minutes from the facility, he favours telephone consultations when medically suitable.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland appears symmetrically enlarged without palpable nodules. General assessment remains unremarkable. Vital signs are stable. There are no clinical indicators of systemic disease or lymphadenopathy.

Patient info: retired police officer; Married; Lives alone.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 45 min/day; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care; Physiotherapy — lower back, six sessions.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.76 +/- 0.12   (95% CI 0.53-0.99)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.12  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.80 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant a change in management?
  - previous_notes (get_previous_notes) -> What was the prior management plan and what was agreed upon with the patient?

This case hinges on the findings from the retrieved documents, specifically the mpMRI report and the PSA trend, to determine if the guideline criterion for re-biopsy is met or if other factors necessitate a different path. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the structured panel, failing to incorporate the context of the mpMRI prose, the PSA velocity (1.32 ng/mL/yr), and the specific PI-RADS 4 score in relation to the guideline criterion.
The prior did not weigh the clinical significance of the rising PSA (from 5.4 to 6.0 ng/mL) against the prior negative biopsy status.
The prior did not account for the specific guideline criterion that mandates re-biopsy based on a PI-RADS 4-5 lesion.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability (0.76), but the guideline criterion is specific: re-biopsy is indicated for a PI-RADS 4-5 lesion, not just a high csPCa probability.
The prior's epistemic error (dp=0.12) suggests the suggestion is not extremely firm, which conflicts with the guideline's "Strong" recommendation for the specific imaging finding.
The prior failed to account for the potential for the PI-RADS 4 lesion to be the sole driver for the decision, irrespective of the overall csPCa probability.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Is the PSA trend significant enough to warrant a change in management?
previous_notes - What was the prior management plan and what was agreed upon with the patient?
laboratory_results - (Dropped by Moderator, but if retrieved, it might clarify PSA density context).

GUIDELINE ANCHOR
The guideline states: "Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion in the right peripheral zone mid-gland, approximately 18 mm. The report notes a focal hypointense abnormality with diffusion restriction and focal enhancement.
get_psa_trend
PSA trend: PSA increased from 2.5 ng/mL (Nov 2023) to 1.4 ng/mL (Jun 2024), and then to 6.0 ng/mL (Jan 2025).
get_previous_notes
Previous notes: A prior biopsy was performed in June 2024, which yielded negative results. The patient was redirected to urology due to sustained PSA elevation and PI-RADS 4 findings.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents provided sufficient information regarding the PSA trend and imaging findings.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the right peripheral zone mid-gland, which meets the guideline criterion for re-biopsy.
- PSA trend: Significant rise in PSA from 1.4 ng/mL (Jun 2024) to 6.0 ng/mL (Jan 2025).
- Previous notes: The patient has a history of a prior negative biopsy despite imaging findings, suggesting the need for reassessment.

AGAINST sampling this patient now:
- Previous notes: The prior biopsy was negative.

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy based on the presence of a PI-RADS 4 lesion and the rising PSA, aligning with the expert protocol criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 4 lesion in the MRI and the significant PSA trend, directly supports the guideline criterion for re-biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to proceed with a targeted biopsy is supported by convergence across all inputs. The guideline criterion mandates re-biopsy for a PI-RADS 4-5 lesion, which was confirmed by the retrieved MRI report showing a PI-RADS 4 lesion. This finding, combined with the significant PSA trend from 1.4 ng/mL to 6.0 ng/mL, directly aligns with the expert protocol. The statistical prior also suggested biopsy, and the retrieved evidence confirmed the clinical necessity for further sampling.

Variables that carried weight: bx=important, age=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
